Showing results (51-60 of 68) with videos related to
Sort By:
Pageof 7
Clinical Lung Cancer|January 29, 2011
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trialPrimo N Lara, Jeff Longmate, Karen Reckamp, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2011
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trialBarbara J Gitlitz, Denice D Tsao-Wei, Susan Groshen, et al.Oncotarget|October 4, 2017
Gene methylation biomarkers in sputum as a classifier for lung cancer riskShuguang Leng, Guodong Wu, Donna M Klinge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancersRamesh K Ramanathan, Merrill J Egorin, Julie L Eiseman, et al.Journal for Immunotherapy of Cancer|January 11, 2021
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II studySuchita Pakkala, Kristin Higgins, Zhengjia Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2023
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief ReportDong-Wan Kim, Sang-We Kim, D Ross Camidge, et al.BMJ Open|January 26, 2022
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trialPeey Sei Kok, Patrick M Forde, Brett Hughes, et al.Clinical Lung Cancer|August 19, 2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)Jyoti D Patel, Ju-Whei Lee, David P Carbone, et al.Nature Communications|March 8, 2025
Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancerChangfa Shu, Jianfeng Li, Jin Rui, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2013
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancerMark A Socinski, Jonathan Goldman, Iman El-Hariry, et al.Pageof 7